Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

Samir D. Undevia, Nicholas J. Vogelzang, Ann M. Mauer, Linda Janisch, Sridhar Mani, Mark J. Ratain

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-β-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. CEP-2563 was developed because of the limited aqueous solubility of CEP-751. Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. CEP-2563 was administered over 1 hour via a central venous catheter once daily for five consecutive days every three weeks. A rapid dose titration strategy with initial single patient cohorts and 100% dose escalations was used. With the appearance of drug-related toxicity, escalations were decreased to 50% or 25% and cohorts were expanded to 3 or 6 patients until establishment of the MTD. Dose escalation rapidly proceeded to 320 mg/m 2/d. The dose limiting toxicities (DLTs) observed were grade 3 hypotension and grade 2 allergic reaction. Other toxicities included anemia, thrombocytopenia, anorexia, asthenia, diarrhea, fatigue, headache, nausea, vomiting, and rash. Pharmacokinetic analysis showed that CEP-2563 is reliably converted to CEP-751. This study demonstrated that single agent CEP-2563 therapy is feasible with acceptable toxicities. The recommended phase II dose is 256 mg/m 2/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial.

Original languageEnglish (US)
Pages (from-to)449-458
Number of pages10
JournalInvestigational New Drugs
Volume22
Issue number4
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Clinical Trials, Phase I
Receptor Protein-Tyrosine Kinases
Neoplasms
Maximum Tolerated Dose
Pharmacokinetics
Asthenia
Central Venous Catheters
CEP 2563
Anorexia
Exanthema
Drug-Related Side Effects and Adverse Reactions
Thrombocytopenia
Hypotension
Solubility
Nausea
Vomiting
Fatigue
Headache
Anemia
Diarrhea

Keywords

  • CEP-2563
  • maximum tolerated dose
  • pharmacokinetics
  • phase I clinical trial
  • toxicity

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. / Undevia, Samir D.; Vogelzang, Nicholas J.; Mauer, Ann M.; Janisch, Linda; Mani, Sridhar; Ratain, Mark J.

In: Investigational New Drugs, Vol. 22, No. 4, 11.2004, p. 449-458.

Research output: Contribution to journalArticle

Undevia, Samir D. ; Vogelzang, Nicholas J. ; Mauer, Ann M. ; Janisch, Linda ; Mani, Sridhar ; Ratain, Mark J. / Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. In: Investigational New Drugs. 2004 ; Vol. 22, No. 4. pp. 449-458.
@article{fce64cc0584b4d6ebd6a37db9df24626,
title = "Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors",
abstract = "CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-β-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. CEP-2563 was developed because of the limited aqueous solubility of CEP-751. Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. CEP-2563 was administered over 1 hour via a central venous catheter once daily for five consecutive days every three weeks. A rapid dose titration strategy with initial single patient cohorts and 100{\%} dose escalations was used. With the appearance of drug-related toxicity, escalations were decreased to 50{\%} or 25{\%} and cohorts were expanded to 3 or 6 patients until establishment of the MTD. Dose escalation rapidly proceeded to 320 mg/m 2/d. The dose limiting toxicities (DLTs) observed were grade 3 hypotension and grade 2 allergic reaction. Other toxicities included anemia, thrombocytopenia, anorexia, asthenia, diarrhea, fatigue, headache, nausea, vomiting, and rash. Pharmacokinetic analysis showed that CEP-2563 is reliably converted to CEP-751. This study demonstrated that single agent CEP-2563 therapy is feasible with acceptable toxicities. The recommended phase II dose is 256 mg/m 2/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial.",
keywords = "CEP-2563, maximum tolerated dose, pharmacokinetics, phase I clinical trial, toxicity",
author = "Undevia, {Samir D.} and Vogelzang, {Nicholas J.} and Mauer, {Ann M.} and Linda Janisch and Sridhar Mani and Ratain, {Mark J.}",
year = "2004",
month = "11",
doi = "10.1023/B:DRUG.0000036687.26604.8c",
language = "English (US)",
volume = "22",
pages = "449--458",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

AU - Undevia, Samir D.

AU - Vogelzang, Nicholas J.

AU - Mauer, Ann M.

AU - Janisch, Linda

AU - Mani, Sridhar

AU - Ratain, Mark J.

PY - 2004/11

Y1 - 2004/11

N2 - CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-β-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. CEP-2563 was developed because of the limited aqueous solubility of CEP-751. Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. CEP-2563 was administered over 1 hour via a central venous catheter once daily for five consecutive days every three weeks. A rapid dose titration strategy with initial single patient cohorts and 100% dose escalations was used. With the appearance of drug-related toxicity, escalations were decreased to 50% or 25% and cohorts were expanded to 3 or 6 patients until establishment of the MTD. Dose escalation rapidly proceeded to 320 mg/m 2/d. The dose limiting toxicities (DLTs) observed were grade 3 hypotension and grade 2 allergic reaction. Other toxicities included anemia, thrombocytopenia, anorexia, asthenia, diarrhea, fatigue, headache, nausea, vomiting, and rash. Pharmacokinetic analysis showed that CEP-2563 is reliably converted to CEP-751. This study demonstrated that single agent CEP-2563 therapy is feasible with acceptable toxicities. The recommended phase II dose is 256 mg/m 2/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial.

AB - CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-β-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. CEP-2563 was developed because of the limited aqueous solubility of CEP-751. Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. CEP-2563 was administered over 1 hour via a central venous catheter once daily for five consecutive days every three weeks. A rapid dose titration strategy with initial single patient cohorts and 100% dose escalations was used. With the appearance of drug-related toxicity, escalations were decreased to 50% or 25% and cohorts were expanded to 3 or 6 patients until establishment of the MTD. Dose escalation rapidly proceeded to 320 mg/m 2/d. The dose limiting toxicities (DLTs) observed were grade 3 hypotension and grade 2 allergic reaction. Other toxicities included anemia, thrombocytopenia, anorexia, asthenia, diarrhea, fatigue, headache, nausea, vomiting, and rash. Pharmacokinetic analysis showed that CEP-2563 is reliably converted to CEP-751. This study demonstrated that single agent CEP-2563 therapy is feasible with acceptable toxicities. The recommended phase II dose is 256 mg/m 2/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial.

KW - CEP-2563

KW - maximum tolerated dose

KW - pharmacokinetics

KW - phase I clinical trial

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=10244241837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244241837&partnerID=8YFLogxK

U2 - 10.1023/B:DRUG.0000036687.26604.8c

DO - 10.1023/B:DRUG.0000036687.26604.8c

M3 - Article

VL - 22

SP - 449

EP - 458

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -